The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients
Testing for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID – exploiting liquid biopsies to advance cancer precision medicine – investigates the potential of additional non-invasive tools for guiding...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2022-08-01
|
| Series: | Journal of Laboratory Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/labmed-2022-0071 |
| _version_ | 1811324186365263872 |
|---|---|
| author | Mack Matthias Broche Julian George Stephen Hajjari Zahra Janke Florian Ranganathan Lavanya Ashouri Mohammadreza Bleul Sabine Desuki Alexander Engels Cecilia Fliedner Stephanie M.J. Hartmann Nils Hummel Michael Janning Melanie Kiel Alexander Köhler Thomas Koschade Sebastian Lablans Martin Lambarki Mohamed Loges Sonja Lueong Smiths Meyer Sandra Ossowski Stephan Scherer Florian Schroeder Christopher Skowronek Patrick Thiede Christian Uhl Barbara Vehreschild Jörg Janne von Bubnoff Nikolas Wagner Sebastian Werner Tamara V. Westphalen C. Benedikt Fresser Patrizia Sültmann Holger Tinhofer Ingeborg Winter Christof |
| author_facet | Mack Matthias Broche Julian George Stephen Hajjari Zahra Janke Florian Ranganathan Lavanya Ashouri Mohammadreza Bleul Sabine Desuki Alexander Engels Cecilia Fliedner Stephanie M.J. Hartmann Nils Hummel Michael Janning Melanie Kiel Alexander Köhler Thomas Koschade Sebastian Lablans Martin Lambarki Mohamed Loges Sonja Lueong Smiths Meyer Sandra Ossowski Stephan Scherer Florian Schroeder Christopher Skowronek Patrick Thiede Christian Uhl Barbara Vehreschild Jörg Janne von Bubnoff Nikolas Wagner Sebastian Werner Tamara V. Westphalen C. Benedikt Fresser Patrizia Sültmann Holger Tinhofer Ingeborg Winter Christof |
| author_sort | Mack Matthias |
| collection | DOAJ |
| description | Testing for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID – exploiting liquid biopsies to advance cancer precision medicine – investigates the potential of additional non-invasive tools for guiding therapy decisions and monitoring of advanced cancer patients. The term “liquid biopsy” (LB) refers to non-invasive analysis of tumor-derived circulating material such as cell-free DNA in blood samples from cancer patients. Although recent technological advances allow sensitive and specific detection of LB biomarkers, only few LB assays have entered clinical routine to date. EXLIQUID is a German Cancer Consortium (DKTK)-wide joint funding project that aims at establishing LBs as a minimally-invasive tool to analyze molecular changes in circulating tumor DNA (ctDNA). Here, we present the structure, clinical aim, and methodical approach of the new DKTK EXLIQUID consortium. Within EXLIQUID, we will set up a multicenter repository of high-quality LB samples from patients participating in DKTK MASTER and local molecular tumor boards, which use molecular profiles of tumor tissues to guide targeted therapies. We will develop LB assays for monitoring of therapy efficacy by the analysis of tumor mutant variants and tumor-specific DNA methylation patterns in ctDNA from these patients. By bringing together LB experts from all DKTK partner sites and exploiting the diversity of their particular expertise, complementary skills and technologies, the EXLIQUID consortium addresses the challenges of translating LBs into the clinic. The DKTK structure provides EXLIQUID a unique position for the identification of liquid biomarkers even in less common tumor types, thereby extending the group of patients benefitting from non-invasive LB testing. Besides its scientific aims, EXLIQUID is building a valuable precision oncology cohort and LB platform which will be available for future collaborative research studies within the DKTK and beyond. |
| first_indexed | 2024-04-13T14:09:38Z |
| format | Article |
| id | doaj.art-5ef881dedc404185a61e429fb791ee07 |
| institution | Directory Open Access Journal |
| issn | 2567-9430 2567-9449 |
| language | English |
| last_indexed | 2024-04-13T14:09:38Z |
| publishDate | 2022-08-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Journal of Laboratory Medicine |
| spelling | doaj.art-5ef881dedc404185a61e429fb791ee072022-12-22T02:43:49ZengDe GruyterJournal of Laboratory Medicine2567-94302567-94492022-08-0146432133010.1515/labmed-2022-0071The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patientsMack Matthias0Broche Julian1George Stephen2Hajjari Zahra3Janke Florian4Ranganathan Lavanya5Ashouri Mohammadreza6Bleul Sabine7Desuki Alexander8Engels Cecilia9Fliedner Stephanie M.J.10Hartmann Nils11Hummel Michael12Janning Melanie13Kiel Alexander14Köhler Thomas15Koschade Sebastian16Lablans Martin17Lambarki Mohamed18Loges Sonja19Lueong Smiths20Meyer Sandra21Ossowski Stephan22Scherer Florian23Schroeder Christopher24Skowronek Patrick25Thiede Christian26Uhl Barbara27Vehreschild Jörg Janne28von Bubnoff Nikolas29Wagner Sebastian30Werner Tamara V.31Westphalen C. Benedikt32Fresser Patrizia33Sültmann Holger34Tinhofer Ingeborg35Winter Christof36School of Medicine, Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, GermanyInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, GermanyDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Berlin, GermanyWest German Cancer Center, Bridge Institute of Experimental Tumor Therapy, University Hospital Essen, Essen, GermanyDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Medicine I, Medical Center – University of Freiburg, Freiburg, GermanySchool of Medicine, Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, GermanyDepartment of Medicine I, Medical Center – University of Freiburg, Freiburg, GermanyUniversity Cancer Center (UCT), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, GermanyCharité University Hospital Berlin, Berlin, GermanyUniversity Cancer Center Schleswig-Holstein, University Medical Center Schleswig-Holstein, Kiel/Lübeck, GermanyInstitute of Pathology, University Medical Center JGU Mainz, Mainz, GermanyCharité University Hospital Berlin, Berlin, GermanyDKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, GermanyComplex Data Processing in Medical Informatics, University Medical Center Mannheim, Mannheim, GermanyComplex Data Processing in Medical Informatics, University Medical Center Mannheim, Mannheim, GermanyGerman Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, German Cancer Research Center (DKFZ), Heidelberg, GermanyComplex Data Processing in Medical Informatics, University Medical Center Mannheim, Mannheim, GermanyComplex Data Processing in Medical Informatics, University Medical Center Mannheim, Mannheim, GermanyDKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, GermanyWest German Cancer Center, Bridge Institute of Experimental Tumor Therapy, University Hospital Essen, Essen, GermanyUniversity Hospital Frankfurt, Frankfurt, GermanyInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, GermanyDepartment of Medicine I, Medical Center – University of Freiburg, Freiburg, GermanyInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, GermanyComplex Data Processing in Medical Informatics, University Medical Center Mannheim, Mannheim, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden, GermanyUniversity Hospital Frankfurt, Frankfurt, GermanyUniversity Hospital Frankfurt, Frankfurt, GermanyUniversity Cancer Center Schleswig-Holstein, University Medical Center Schleswig-Holstein, Kiel/Lübeck, GermanyGerman Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, German Cancer Research Center (DKFZ), Heidelberg, GermanyMedical Center, Medical Faculty, Institute for Surgical Pathology, University of Freiburg, Freiburg, GermanyComprehensive Cancer Center Munich & Department of Medicine III, Ludwig Maximilian University of Munich, Munich, GermanySchool of Medicine, Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, GermanyDivision of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Berlin, GermanySchool of Medicine, Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, GermanyTesting for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID – exploiting liquid biopsies to advance cancer precision medicine – investigates the potential of additional non-invasive tools for guiding therapy decisions and monitoring of advanced cancer patients. The term “liquid biopsy” (LB) refers to non-invasive analysis of tumor-derived circulating material such as cell-free DNA in blood samples from cancer patients. Although recent technological advances allow sensitive and specific detection of LB biomarkers, only few LB assays have entered clinical routine to date. EXLIQUID is a German Cancer Consortium (DKTK)-wide joint funding project that aims at establishing LBs as a minimally-invasive tool to analyze molecular changes in circulating tumor DNA (ctDNA). Here, we present the structure, clinical aim, and methodical approach of the new DKTK EXLIQUID consortium. Within EXLIQUID, we will set up a multicenter repository of high-quality LB samples from patients participating in DKTK MASTER and local molecular tumor boards, which use molecular profiles of tumor tissues to guide targeted therapies. We will develop LB assays for monitoring of therapy efficacy by the analysis of tumor mutant variants and tumor-specific DNA methylation patterns in ctDNA from these patients. By bringing together LB experts from all DKTK partner sites and exploiting the diversity of their particular expertise, complementary skills and technologies, the EXLIQUID consortium addresses the challenges of translating LBs into the clinic. The DKTK structure provides EXLIQUID a unique position for the identification of liquid biomarkers even in less common tumor types, thereby extending the group of patients benefitting from non-invasive LB testing. Besides its scientific aims, EXLIQUID is building a valuable precision oncology cohort and LB platform which will be available for future collaborative research studies within the DKTK and beyond.https://doi.org/10.1515/labmed-2022-0071liquid profilingmolecular profilingprecision oncology |
| spellingShingle | Mack Matthias Broche Julian George Stephen Hajjari Zahra Janke Florian Ranganathan Lavanya Ashouri Mohammadreza Bleul Sabine Desuki Alexander Engels Cecilia Fliedner Stephanie M.J. Hartmann Nils Hummel Michael Janning Melanie Kiel Alexander Köhler Thomas Koschade Sebastian Lablans Martin Lambarki Mohamed Loges Sonja Lueong Smiths Meyer Sandra Ossowski Stephan Scherer Florian Schroeder Christopher Skowronek Patrick Thiede Christian Uhl Barbara Vehreschild Jörg Janne von Bubnoff Nikolas Wagner Sebastian Werner Tamara V. Westphalen C. Benedikt Fresser Patrizia Sültmann Holger Tinhofer Ingeborg Winter Christof The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients Journal of Laboratory Medicine liquid profiling molecular profiling precision oncology |
| title | The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| title_full | The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| title_fullStr | The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| title_full_unstemmed | The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| title_short | The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| title_sort | dktk exliquid consortium exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients |
| topic | liquid profiling molecular profiling precision oncology |
| url | https://doi.org/10.1515/labmed-2022-0071 |
| work_keys_str_mv | AT mackmatthias thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT brochejulian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT georgestephen thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hajjarizahra thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT jankeflorian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ranganathanlavanya thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ashourimohammadreza thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT bleulsabine thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT desukialexander thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT engelscecilia thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT fliednerstephaniemj thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hartmannnils thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hummelmichael thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT janningmelanie thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT kielalexander thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT kohlerthomas thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT koschadesebastian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lablansmartin thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lambarkimohamed thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT logessonja thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lueongsmiths thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT meyersandra thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ossowskistephan thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT schererflorian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT schroederchristopher thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT skowronekpatrick thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT thiedechristian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT uhlbarbara thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT vehreschildjorgjanne thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT vonbubnoffnikolas thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT wagnersebastian thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT wernertamarav thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT westphalencbenedikt thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT fresserpatrizia thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT sultmannholger thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT tinhoferingeborg thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT winterchristof thedktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT mackmatthias dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT brochejulian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT georgestephen dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hajjarizahra dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT jankeflorian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ranganathanlavanya dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ashourimohammadreza dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT bleulsabine dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT desukialexander dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT engelscecilia dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT fliednerstephaniemj dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hartmannnils dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT hummelmichael dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT janningmelanie dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT kielalexander dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT kohlerthomas dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT koschadesebastian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lablansmartin dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lambarkimohamed dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT logessonja dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT lueongsmiths dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT meyersandra dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT ossowskistephan dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT schererflorian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT schroederchristopher dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT skowronekpatrick dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT thiedechristian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT uhlbarbara dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT vehreschildjorgjanne dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT vonbubnoffnikolas dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT wagnersebastian dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT wernertamarav dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT westphalencbenedikt dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT fresserpatrizia dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT sultmannholger dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT tinhoferingeborg dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients AT winterchristof dktkexliquidconsortiumexploitingliquidbiopsiestoadvancecancerprecisionmedicineformoleculartumorboardpatients |